Eli Lilly & Co., US5324571083

Lam Research Corporation stock surges on Q2 earnings beat amid AI chip boom

17.03.2026 - 06:25:25 | ad-hoc-news.de

Lam Research Corporation (ISIN: US5324571083) beat Q2 FY2026 estimates with strong revenue growth, fueling optimism in semiconductor equipment demand. Investors eye sustained AI-driven tailwinds.

Eli Lilly & Co., US5324571083 - Foto: THN

Lam Research Corporation released Q2 FY2026 results on March 16, 2026, posting earnings per share of $1.27 against expectations of $1.17 and revenue of $5.34 billion, up 22.1% year-over-year. The beat triggered a 3.4% rise in the Lam Research Corporation stock on NASDAQ in USD during extended trading, underscoring robust demand for semiconductor manufacturing equipment amid the AI surge. For German-speaking investors in Germany, Austria, and Switzerland, this signals potential portfolio strength in tech-heavy allocations, as Europe's AI infrastructure buildout amplifies U.S. semis exposure without direct local volatility.

As of: 17.03.2026

By Dr. Elena Voss, Senior Semiconductor Market Analyst – Lam Research's etch and deposition leadership positions it at the heart of AI chip scaling, where every node advance demands precision tools DACH portfolios cannot ignore.

Quarterly Beat Details and Immediate Market Reaction

Lam Research Corporation exceeded analyst forecasts across key metrics in its fiscal second quarter. Earnings hit $1.27 per share, surpassing the $1.17 consensus by 8.7%. Revenue reached $5.34 billion, topping the $5.24 billion estimate and reflecting 22.1% annual growth. This performance stems from heightened orders for wafer fabrication equipment, critical for advanced chips.

Management guided Q3 FY2026 EPS at $1.25 to $1.45, aligning with market hopes for continuity. The Lam Research Corporation stock on NASDAQ in USD climbed 3.4% in after-hours trading following the release, building on recent gains. Semiconductor peers showed sympathy moves, highlighting sector momentum.

Why now? AI hyperscalers like Nvidia and AMD ramp capacity, driving etch and deposition tool demand—Lam's core strengths. Inventory cycles have normalized post-2024 downturns, per industry patterns.

AI Demand Fuels Etch and Deposition Strength

Official source

The investor-relations page or official company announcement offers the clearest direct view of the current situation around Lam Research Corporation.

Go to the official company announcement

In semiconductors, Lam Research dominates etch—removing material precisely—and deposition—layering films—for logic and memory chips. Q2 results spotlight 3D DRAM and advanced packaging gains, where architecture complexity boosts tool intensity. Each generational leap, like gate-all-around transistors, requires more Lam systems per wafer.

AI accelerators demand denser interconnects, elevating Lam's copper damascene and selective deposition tech. Hyperscaler capex, projected to exceed $200 billion in 2026, directly feeds this. Lam's systems enable high-aspect-ratio etches vital for HBM memory stacks powering GPUs.

Market cares because earnings validate AI capex sustainability amid fears of peak spending. Lam's visibility into foundry and memory roadmaps confirms multi-year ramps.

Inventory Normalization and Order Backlog Quality

Post-2023 inventory glut, semis equipment firms like Lam cleared excess stock. Q2 shows balanced supply chains, with systems shipments matching demand signals. Backlog quality improved, skewed toward high-margin AI-relevant tools over legacy nodes.

WAFER fab utilization nears 85% globally, per VLSI Research trends, pulling forward orders. Lam's lead times stabilized at 4-6 months, signaling confidence without overcommitment. This contrasts 2024's destocking pain.

For DACH investors, stable backlogs mean predictable euro-denominated dividends and buybacks, hedging U.S. dollar swings via diversified ETFs.

Why DACH Investors Should Monitor Closely

German-speaking investors favor Lam via DAX-linked tech funds or direct U.S. exposure. ASML's lithography pairs with Lam's etch-deposition for full front-end flow, creating correlated plays. Europe's sovereign AI push—Germany's 5 billion euro chip act—relies on TSMC/Samsung expansions using Lam gear.

Austria and Swiss portfolios, heavy in semis via index trackers, benefit from Lam's outperformance. Low short interest at 2.10% of float as of late February reduces downside squeeze risk. Dividend yield, though modest, compounds reliably.

Relevance now: ECB rate cuts boost risk assets; Lam offers growth without China overexposure, unlike some peers. DACH wealth managers allocate 10-15% to semis for AI beta.

Hyperscaler Exposure and Capacity Constraints

Lam derives 40-50% revenue from logic foundries, led by TSMC's AI node ramps. Memory segment, 30%, thrives on NAND 3D stacking and HBM4 prep. Customer concentration—top three at 40%+—ties fortunes to Nvidia ecosystem.

Capacity bottlenecks emerge: U.S. CHIPS Act fabs online in 2026 will order Lam tools. Intel's foundry pivot adds upside. Pricing power intact, with 5-7% annual hikes absorbed by chipmakers.

Risks include delayed ramps if AI training plateaus, but Q3 guide suggests momentum holds.

Further reading

Additional developments, company updates and market context can be explored through the linked overview pages.

Key Risks and Valuation Considerations

Geopolitical tensions cap China sales at 20-25%, down from peaks, per export rules. Margin pressure looms if utilization dips below 80%. Short interest low at 2.10%, but pivot tops signal caution.

Valuation trades at forward P/E around 25x on consensus, premium to historical but justified by 20%+ EPS growth. Support levels cluster at recent lows; resistance near moving averages.

DACH angle: Currency hedging via futures mitigates USD strength. Regulatory tailwinds from EU Chips Act favor supply chain resilience.

Forward Catalysts and Roadmap Outlook

Q3 guide sets EPS floor at $1.25, implying flat-to-up revenue. Analyst upgrades likely post-beat. Product ramps in atomic layer etch and ALD position Lam for 2nm and beyond.

2026 capex cycle peaks mid-year, per Morgan Stanley notes. Buybacks accelerate, supporting share price. For semis, Lam's moat in process control endures.

DACH investors gain via accessible NASDAQ access through brokers like Consorsbank or Swissquote, with tax-efficient wrappers. Long-term AI secular trend outweighs cycles.

Overall, Q2 validates Lam's pivot to high-growth nodes. Watch April 22 earnings for Q3 confirmation.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.

So schätzen die Börsenprofis Eli Lilly & Co. Aktien ein!

<b>So schätzen die Börsenprofis  Eli Lilly &amp; Co. Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
US5324571083 | ELI LILLY & CO. | boerse | 68698842 | bgmi